GT Biopharma Inc

NASDAQ:GTBP   3:54:47 PM EDT
3.58
+0.04 (+1.13%)
5:12:20 PM EDT: $3.75 +0.17 (+4.75%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

GT Biopharma Inc Stock, NASDAQ:GTBP

315 Montgomery Street, 10th Floor, San Francisco, California 94104
United States of America
Phone: +1.415.919.4040
Number of Employees: 1

Description

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.